<SEC-DOCUMENT>0001157523-16-006807.txt : 20160930
<SEC-HEADER>0001157523-16-006807.hdr.sgml : 20160930
<ACCEPTANCE-DATETIME>20160930172803
ACCESSION NUMBER:		0001157523-16-006807
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160929
FILED AS OF DATE:		20160930
DATE AS OF CHANGE:		20160930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		161913759

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51430467.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-family: Times New Roman; font-size: 16pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 16pt"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-family: Times New Roman; font-size: 16pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="color: #000000; width: 100%; text-align: center; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 14pt"><b>FORM 6-K</b></font>
    </p>
    <hr style="color: #000000; width: 100%; text-align: center; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-family: Times New Roman; font-size: 12pt">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-family: Times New Roman; font-size: 12pt"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-family: Times New Roman; font-size: 12pt"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Dated</b></font><font style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-family: Times New Roman; font-size: 10pt"><b>September
      29, 2016</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="color: #000000; width: 100%; text-align: center; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br><br>
    </p>
    <hr style="color: #000000; width: 100%; text-align: center; height: 1.0 pt">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principal executive offices)</b>
    </p>
    <p style="text-align: center">

    </p>
    <hr style="color: #000000; width: 100%; text-align: center; height: 1.0 pt">


    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F:</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Form 20-F &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-family: Times New Roman; font-size: 10pt">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Yes &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman; font-size: 10pt">
      No &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-family: Times New Roman; font-size: 10pt">If &quot;Yes&quot; is
      marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): Not a</font>pplicable.<br>
    </p>
    <div style="margin-right: 0pt; width: 100%; margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><br style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized. </font>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; width: 100%; margin-bottom: 10.0px; font-family: Times New Roman">
      <tr>
        <td valign="top" style="padding-left: 0.0px; width: 6%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated:
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 44%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            September 29, 2016
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: center">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-bottom: 2.0px; padding-left: 0.0px; width: 6%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-bottom: 2.0px; padding-left: 0.0px; width: 44%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-bottom: 2.0px; padding-left: 0.0px; width: 3%; text-align: left">
          By:
        </td>
        <td colspan="2" valign="top" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: left; border-bottom-width: 1.0pt">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Michael R. Martin
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 3%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 5%; text-align: left">
          Name:
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 42%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Michael R. Martin
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; width: 6%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 44%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 5%; text-align: left">
          Title:
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 42%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Operating Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="width: 100%; margin-right: 0pt; margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-size: 10pt; font-family: Times New Roman; text-align: center">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; width: 100%; margin-bottom: 10.0px; font-family: Times New Roman">
      <tr>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; width: 7%; border-bottom-color: black; text-align: left; border-bottom-width: 1.0pt">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td valign="bottom" style="padding-bottom: 2.0px; padding-left: 0.0px; width: 5%; text-align: left">
          &#160;
        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; width: 88%; border-bottom-color: black; text-align: left; border-bottom-width: 1.0pt">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 88%; text-align: left">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; width: 7%; padding-right: 0.0px; white-space: nowrap; text-align: left">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 88%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            News Release &#8211; <b>AURINIA ANNOUNCES THAT VOCLOSPORIN
            ACHIEVES PRIMARY AND ALL PRE-SPECIFIED SECONDARY ENDPOINTS IN ITS
            PHASE IIb AURA-LV STUDY FOR LUPUS NEPHRITIS</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51430467ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Aurinia
      Announces That Voclosporin Achieves Primary and All Pre-Specified
      Secondary Endpoints in Its Phase IIb </b></font><b><i><font style="font-family: Times New Roman; font-size: 12pt">AURA-LV</font></i><font style="font-family: Times New Roman; font-size: 12pt">
      Study for Lupus Nephritis (LN)</font></b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        <i><font style="font-family: Times New Roman; font-size: 12pt"><b>AURA-LV
        is the first global active LN study to meet its primary endpoint and
        all of its 24-week pre-specified secondary endpoints</b></font></i>
      </li>
      <li style="margin-bottom: 10.0px">
        <i><font style="font-family: Times New Roman; font-size: 12pt"><b>Comprehensive
        mortality review concludes that deaths in the AURA-LV study appear to
        be unrelated to study drug and consistent with complications of LN</b></font></i>
      </li>
      <li style="margin-bottom: 10.0px">
        <i><font style="font-family: Times New Roman; font-size: 12pt"><b>Additional
        efficacy and safety analyses from the AURA study will be presented and
        webcast live on Friday, September 30</b></font><b><sup><font style="font-family: Times New Roman; font-size: 12pt">th</font></sup><font style="font-family: Times New Roman; font-size: 12pt">
        at 8:00am</font></b></i>
      </li>
    </ul>
    <p>

    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--September 29, 2016--Aurinia
      Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (&#8220;Aurinia&#8221; or the
      &#8220;Company&#8221;) a clinical stage biopharmaceutical company focused on the
      global immunology market, today announced that in addition to
      voclosporin (23.7 mg BID) achieving its primary endpoint of Complete
      Remission (CR) at 24 weeks, both doses of voclosporin when added to the
      current standard of care of Mycophenolate Mofetil (MMF) and a forced
      oral corticosteroid taper have met all 24-week pre-specified secondary
      endpoints vs the control group. These pre-specified endpoints include:
      Partial Remission (PR), which is measured by a &#8805;50% reduction in UPCR
      with no concomitant use of rescue medication; time to CR and PR;
      reduction in Systemic Lupus Erythematosus Disease Activity Index or
      SLEDAI score; and reduction in UPCR over the 24-week treatment period.
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 8pt; width: 100%; margin-bottom: 10.0px; font-family: Times New Roman">
      <tr>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <b>Pre-specified Secondary Endpoint</b>
        </td>
        <td>
          &#160;
        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <b>Control</b>
        </td>
        <td>
          &#160;
        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <b>Low Dose VCS</b>

          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>(23.7mg BID)</b>
          </p>
        </td>
        <td>
          &#160;
        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <b>High Dose VCS</b>

          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>(39.5mg BID)</b>
          </p>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: left; border-bottom-width: 1.0pt">
          <b>Time to Complete Remission (TTCR) </b>[median]
        </td>
        <td>

        </td>
        <td rowspan="2" valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          Not achieved
        </td>
        <td>

        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          19.7 weeks
        </td>
        <td>

        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          23.4 weeks
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p&lt;.001</b></i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p=.001</b></i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: left; border-bottom-width: 1.0pt">
          <b>Partial Remission </b>(as measured by UPCR reduction of &#8805; 50%
          from baseline)
        </td>
        <td>

        </td>
        <td rowspan="2" valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          49%
        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          70%
        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          66%
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p=.007</b></i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p=.024</b></i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: left; border-bottom-width: 1.0pt">
          <b>Time to Partial Remission (TTPR) </b>[median]
        </td>
        <td>

        </td>
        <td rowspan="2" valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          6.6 weeks
        </td>
        <td>

        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          4.1 weeks
        </td>
        <td>

        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          4.4 weeks
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p=.002</b></i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p=.003</b></i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: left; border-bottom-width: 1.0pt">
          <b>SLEDAI Reduction</b>
        </td>
        <td>

        </td>
        <td rowspan="2" valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          -4.5
        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          -6.3
        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          -7.1
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p=.003</b></i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p=.003</b></i>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: left; border-bottom-width: 1.0pt">
          <b>Reduction in UPCR</b>
        </td>
        <td>

        </td>
        <td rowspan="2" valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          -2.216 mg/mg
        </td>
        <td>

        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          -3.769 mg/mg
        </td>
        <td>

        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          -2.792 mg/mg
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td valign="middle" style="border-bottom-style: solid; padding-left: 0.0px; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p&lt;.001</b></i>
        </td>
        <td>

        </td>
        <td valign="bottom" style="border-bottom-style: solid; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; border-bottom-color: black; text-align: center; border-bottom-width: 1.0pt">
          <i><b>p=.006</b></i>
        </td>
        <td>

        </td>
      </tr>
    </table>
    </div>
    <p>
      <i>All p-values are vs control</i>
    </p>
    <p>
      The AURA-LV study remains ongoing to its 48-week endpoint upon which
      similar and additional secondary analysis will be analysed and presented
      early next year.
    </p>
    <p>
      &#8220;We are thrilled by the results of the AURA study and voclosporin&#8217;s
      potential to shift the treatment paradigm for active lupus nephritis,&#8221;
      said Charles Rowland, CEO of Aurinia. &#8220;The ability to get more patients
      into remission and in a shorter period time than the current standard of
      care can have a significant impact on the long-term outcomes for these
      patients.&#8221;
    </p>
    <div style="width: 100%; margin-right: 0pt; margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      &#8220;LN is a serious and devastating disease that can severely impact a
      patient&#8217;s life,&#8221; said William Pendergraft, MD, PhD, Assistant Professor
      of Medicine in the Division of Nephrology &amp; Hypertension, at the
      University of North Carolina and a Principal Investigator in the study.
      &#8220;Voclosporin has demonstrated it can nearly double the number of
      patients that achieve Complete Remission in the presence of very low
      corticosteroid exposure. Based on these data, I believe this drug has
      the potential to significantly improve the long-term prognosis of my
      patients afflicted with LN and could become an integral component of the
      standard of care.&#8221;
    </p>
    <p>
      The Company will present the full efficacy (including pre-specified and
      ad hoc sub-analyses) and comprehensive safety data during a webcast
      presentation to be held at 8:00am ET. A link to the live webcast and
      slides will be available on the Investors section of the Company&#8217;s
      website at <u>http://www.auriniapharma.com.</u>
    </p>
    <p>
      <i><b>About AURA-LV</b></i><br>The AURA&#8211;LV study or &#8220;Aurinia Urine
      Protein Reduction in Active Lupus Nephritis Study&#8221; compared the efficacy
      of voclosporin added to current standard of care of mycophenolate
      mofetil (MMF, also known as CellCept&#174;) against standard of care with
      placebo in achieving complete remission (CR) in patients with active LN.
      Both arms also received low doses of corticosteroids as background
      therapy. It enrolled 265 patients at centers in over 20 countries
      worldwide. On entry to the study, patients were required to have a
      diagnosis of LN according to established diagnostic criteria (American
      College of Rheumatology) and clinical and biopsy features indicative of
      highly active nephritis.
    </p>
    <p>
      <i><b>About Voclosporin</b></i><br>Voclosporin, an investigational drug,
      is a novel and potentially best-in-class calcineurin inhibitor (&#8220;CNI&#8221;)
      with clinical data in over 2,000 patients in other indications.
      Voclosporin is an immunosuppressant, with a synergistic and dual
      mechanism of action that has the potential to improve near- and
      long-term outcomes in LN when added to standard of care (MMF). By
      inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell
      mediated immune responses. It is made by a modification of a single
      amino acid of the cyclosporine molecule which has shown a more
      predictable pharmacokinetic and pharmacodynamic relationship, an
      increase in potency, an altered metabolic profile, and potential for
      flat dosing. The Company anticipates that upon regulatory approval,
      patent protection for voclosporin will be extended in the United States
      and certain other major markets, including Europe and Japan, until at
      least October 2027 under the Hatch-Waxman Act and comparable laws in
      other countries.
    </p>
    <p>
      <i><b>About Lupus Nephritis (LN)</b></i><br>Lupus Nephritis (LN) in an
      inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE)
      and represents a serious progression of SLE. SLE is a chronic, complex
      and often disabling disorder and affects more than 500,000 people in the
      United States (mostly women). The disease is highly heterogeneous,
      affecting a wide range of organs &amp; tissue systems. It is estimated that
      as many as 60% of all SLE patients have clinical LN requiring treatment.
      Unlike SLE, LN has straightforward disease outcomes where an early
      response correlates with long-term outcomes, measured by proteinuria. In
      patients with LN, renal damage results in proteinuria and/or hematuria
      and a decrease in renal function as evidenced by reduced estimated
      glomerular filtration rate (eGFR), and increased serum creatinine
      levels. LN is debilitating and costly and if poorly controlled, LN can
      lead to permanent and irreversible tissue damage within the kidney,
      resulting in end-stage renal disease (ESRD), thus making LN a serious
      and potentially life-threatening condition.
    </p>
    <p>
      <i><b>About Aurinia</b></i><br>Aurinia is a clinical stage
      biopharmaceutical company focused on developing and commercializing
      therapies to treat targeted patient populations that are suffering from
      serious diseases with a high unmet medical need. The company is
      currently developing voclosporin, an investigational drug, for the
      treatment of lupus nephritis (LN). The company is headquartered in
      Victoria, BC and focuses its development efforts globally. <u>www.auriniapharma.com</u>
    </p>
    <div style="width: 100%; margin-right: 0pt; margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <i><b>Forward Looking Statements</b></i><br>This press release contains
      forward-looking statements, including statements related to Aurinia's
      regulatory strategy (including plans to meet with the U.S. Food and Drug
      Administration to discuss these data and the voclosporin&#8217;s subsequent
      clinical development and path to registration in LN), Aurinia's
      analysis, assessment and conclusions of the results of the AURA-LV
      clinical study, and the efficacy and commercial potential of
      voclosporin. It is possible that such results or conclusions may change
      based on further analyses of these data.&#160;Words such as &quot;plans,&quot;
      &quot;intends,&quot; &#8220;may,&#8221; &quot;will,&quot; &quot;believe,&quot; and similar expressions are
      intended to identify forward-looking statements. These forward-looking
      statements are based upon Aurinia&#8217;s current expectations.
      Forward-looking statements involve risks and uncertainties. Aurinia&#8217;s
      actual results and the timing of events could differ materially from
      those anticipated in such forward-looking statements as a result of
      these risks and uncertainties, which include, without limitation, the
      risk that Aurinia&#8217;s analyses, assessment and conclusions of the results
      of the AURA-LV clinical study set forth in this release may change based
      on further analyses of such data, and the risk that Aurinia&#8217;s clinical
      studies for voclosporin may not lead to regulatory approval. These and
      other risk factors are discussed under &quot;Risk Factors&quot; and elsewhere in
      Aurinia&#8217;s Annual Information Form for the year ended December 31, 2015
      filed with Canadian securities authorities and available at <u>www.sedar.com</u>
      and on Form 40-F with the U.S. Securities Exchange Commission and
      available at <u>www.sec.gov</u>, each as updated by subsequent filings,
      including filings on Form 6-K. Aurinia expressly disclaims any
      obligation or undertaking to release publicly any updates or revisions
      to any forward-looking statements contained herein to reflect any change
      in Aurinia's expectations with regard thereto or any change in events,
      conditions or circumstances on which any such statements are based.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br><i><b>Aurinia</b></i><br>Celia Economides<br>Head of IR &amp;
      Communications<br><u>ceconomides@auriniapharma.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
